European Urology Today October/December 2016

Page 1

European Urology Today Official newsletter of the European Association of Urology

4-5

Vol. 28 No.5 - October/December 2016

London calling

Urology Week in pictures

CEM/SEEM: Roundup reports

Sneak preview on what to expect at EAU17 in London

A glimpse of Europe-wide activities during Urology Week

Overview and highlights from the last editions of the Regional Meetings

20-21

24-26

EAU pledges action to tackle prostate cancer Launch of White Paper on prostate cancer by EAU in January 2017 Prof. Hein Van Poppel Adjunct SecretaryGeneral Leuven (BE)

hendrik.vanpoppel@ uzleuven.be Prostate cancer (PCa) is the most commonly diagnosed cancer in men with more than 417,000 new cases and 92,000 deaths in Europe recorded each year. Currently, 1 in 7 men in Europe will develop detectable PCa before the age of 85. More than two million men in Europe are living with this disease and so it is a strategic priority for the EAU to raise awareness of the impact of PCa and to collaborate to promote more action at EU level. Although significant advances are being made in the fight against the disease, cancer remains a key public health concern and a tremendous burden on European societies. It is for this reason that a range of activities have taken place at EU level to help Member States in the fight against cancer. EU action on cancer The European Code Against Cancer is a European Commission initiative to inform people about actions they can take for themselves or their families to reduce their risk of cancer. The scientific evidence behind the code can be accessed here: http://cancer-code-europe.iarc.fr/index.php/en/ scientific-justification The current fourth edition consists of twelve recommendations that most people can follow without any special skills or advice. The more recommendations people follow, the lower their risk of cancer will be. It has been estimated that almost half of all deaths due to cancer in Europe could be avoided if everyone followed the recommendations. The fourth edition of the Code is published on the website, together with additional information about each recommendation and related aspects of cancer prevention.

more needs to be done to give PCa equal attention, given its impact on the health of European men. From 2009 to 2013, the European Commission (EC) ran the European Partnership for Action Against Cancer to help Member States and other stakeholders tackle cancer more efficiently. In 2014, the EC established the Expert Group on Cancer Control to help in the preparation of EU policy initiatives in this area. The Expert Group, chaired by the EC, brings together representatives from Member States national authorities as well as representatives from patient groups, scientific and medical associations specialised in cancer, organisations working on cancer prevention and industry. More information about the EC’s policy on cancer control, including the work of the Expert Group can be found here: http://ec.europa.eu/health/ major_chronic_diseases/diseases/cancer/index_en. htm#fragment1 Also in 2014, an EU Joint Action on Cancer Control (CANCON) was launched to develop an EU Guide on Quality Improvement in Comprehensive Cancer Control. This Joint Action will finish in 2017 with the final conference in Malta on 14 – 15 February. Please see http://www.cancercontrol.eu/ for more information on this initiative. More recently, the EC initiated a ground-breaking project to develop a European quality assurance scheme for breast cancer services underpinned by accreditation and referring to high quality, evidencebased guidelines. Alongside this, the EC, through its consecutive Research Programmes has supported a number of EU collaborative research projects in cancer, including projects specifically focused on PCa.

"The EAU will lead a campaign to promote the recommendations of the White Paper..."

EAU action on prostate cancer The EAU has a wealth of expertise, scientific resources and tools targeting both clinicians and patients on which the EU work on PCa could build and expand. The EAU has already delivered a range of activities to raise awareness of the importance of PCa and to compile the most comprehensive guidelines The first edition of the Code was published in 1987. worldwide based on the latest scientific evidence. The fourth edition was prepared in 2012–2013 In partnership with Europa Uomo, the EAU organised by cancer specialists, scientists and other experts from a European PCa Awareness Day (EPAD) in 2015, where across the European Union in a project coordinated by key policy makers, scientific experts, European the International Agency for Research on Cancer, urological associations and representatives of patient with financial support from the EU Health Programme. groups gathered at the European Parliament in In formulating the recommendations, the experts took Brussels to discuss the impact of PCa in Europe. into account the latest scientific evidence available. All the experts who contributed to the fourth edition According to recent research, cancer has now were requested to work independently and be guided overtaken cardiovascular disease as the main cause of only by their expert views, not by the position of any death in 12 European countries (Belgium, Denmark, France, Italy, Luxembourg, The Netherlands, Portugal, organisation or institution. Slovenia, Spain, UK, Norway and Israel). This In 2003, the EU Health Ministers unanimously adopted increases the importance of a European effort a Council Recommendation on cancer screening, towards prevention. The most common cancer sites setting out principles of best practice in are breast, colorectal, prostate and lung, and expert opinions agree on the addition of bladder and kidney the early detection of cancer. The Recommendation invited all Member States to take common action to cancer based on the most recent figures of their burden in Europe. implement national population-based screening programmes for breast, cervical and colorectal cancer, The European Multidisciplinary Meeting on Urological with appropriate quality assurance at all levels. PCa was not included in this list and the EAU considers that Cancers (EMUC) focusses on controversial diagnostic issues and treatment strategies during an annual three-day congress with the collaboration of the European Society for Medical Oncology (ESMO), the European Society for Radiotherapy & Oncology (ESTRO), the European Society for Radiology (ESR), the European Society for Pathology (ESP) and the EAU. During the 8th EMUC meeting from 24-27 November in Milan, Italy, Dr. Tit Albreht, coordinator of CANCON, will give an overview of the work of the EU Joint October/December 2016

Action and will explain how the forthcoming Guide on comprehensive cancer control could help to improve diagnosis and care for patients with urological cancers. PCa is the most frequent cancer and the third most common cause of death in men in Europe and has an important impact on healthcare systems. Therefore, I have been leading the production of an EAU White Paper on PCa in close collaboration with the European Prostate Cancer Coalition (EUomo), the European Cancer Patient Coalition (ECPC) and the Association of European Cancer Leagues (ECL). The paper aims to raise awareness of some of the key issues about PCa in Europe and to make the following recommendations for action at European level: • The EU needs to raise men’s awareness of PCa. This is a considerable healthcare problem that would benefit from a uniform EU-wide riskadapted early detection programme. The EU needs to increase funding to improve both the timely diagnosis and treatment of men with PCa. It needs to fund work to better understand the association between potential risk factors and lethal PCa. • European institutions and Member States need to ensure that PCa patients receive high quality, standardised, and integrated care with a focus on a patient-centred multidisciplinary approach. • The EU and its Member States should also ensure equitable access to novel technological tools that enable better diagnosis, treatment and research. The future is likely to encompass risk-adapted treatment programmes that require contemporary imaging and diagnostic tools.

• Fast and equitable access to innovative treatments and personalised medicines should be made for all PCa patients who can benefit from them. • Finally, the EU and its Member States should promote the implementation of cancer survivorship plans, including specific plans for PCa patients, to facilitate the return to a normal life for all European PCa patients. The EAU and other collaborating organisations will launch the White Paper on PCa at an expert meeting on PCa on 24 January 2017 in Brussels, organised by the International Centre for Parliamentary Studies (ICPS) in collaboration with the EAU. The EAU will then lead a campaign to promote the recommendations of the White Paper to all relevant stakeholders at European and national levels in the lead up to the next European Prostate Awareness Day (EPAD), which will take place in autumn 2017 in the European Parliament in Brussels. It remains a strategic priority for the EAU to offer its scientific expertise and to actively engage with the EU institutions and other stakeholders to create a better future for all of Europe’s PCa patients.

Wishing You a Joyful Holiday Season and a Happy New Year!

Apply now for the YUO Leadership for Medical Professionals Course For more details see page 34

www.eau17.org

Cutting-edge Science at Europe’s largest Urology Congress Register now for the early bird fee! Deadline: 16 January 2017

European Urology Today

1


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.
European Urology Today October/December 2016 by European Association of Urology (EAU) - Issuu